Showing 151–175 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Bryant KE, Yuan Y, Engle M, Kurbatova EV, Allen-Blige C, et al.
…ng a large phase 3 clinical trial. Material and methods The Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) study A5349 (S31) is an international, multi-site, randomized, open-label, controlled, non-inferiority phase 3 clinical trial comparing two…
Hamu J Mlyuka, Alphonce Liyoyo, Belinda Nyaulingo, Emmanuel Mpolya, Oscar L Kaswaga, et al.
…rrent combination antibiotic treatment for drug-susceptible tuberculosis (DS-TB) usually takes 6 months to complete. This long duration can compromise clinical outcomes. Although a 4-month regimen including an optimized dose of rifapentine plus moxifloxacin is non-inferior to sta…
Tadesse AW, Cusinato M, Weldemichael GT, Abdurhman T, Assefa D, et al.
Background Non-adherence to tuberculosis treatment increases the risk of poor treatment outcomes. Digital adherence technologies (DATs), including the smart pillbox (EvriMED), aim to improve treatment adherence and are being widely evaluated. As part of the Adherence Support Coal…
Drabarek D, Anh NT, Nhung NV, Hoa NB, Fox GJ, et al.
Background Despite the criticality of adherence to tuberculosis treatment, there is paucity of rigorous experimental research exploring the efficacy of interventions to promote adherence and a greater lack of inquiry addressing the integral role of adherence behaviour. The aim of…
Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, et al.
…improve treatment efficacy while minimizing toxicity during tuberculosis treatment. Study 31/AIDS Clinical Trials Group A5349 represents the largest phase 3 randomized controlled therapeutic trial to date for such an investigation. Objectives: We sought to report pyrazinamide pha…
Butov D, Feshchenko Y, Kuzhko M, Gumenuik M, Yurko K, et al.
…atients with new sputum positive drug-susceptible pulmonary tuberculosis (TB) with tuberculous meningoencephalitis (TM) and human immunodeficiency virus (HIV) co-infection in the intensive phase of treatment. Methods Fifty-four patients with TB/TM and HIV co-infection were enroll…
Ellis T, Chiappi M, García-Trenco A, Al-Ejji M, Sarkar S, et al.
Mycobacterium tuberculosis ( M.tb) has the extraordinary ability to adapt to the administration of antibiotics through the development of resistance mechanisms. By rapidly exporting drugs from within the cytosol, these pathogenic bacteria diminish antibiotic potency and drive the…
Krishnan S, Gupte N, Paradkar M, Gupte A, Naik M, et al.
Some individuals with drug-susceptible pulmonary tuberculosis (PTB) experience tuberculosis recurrence. To evaluate the incidence of and risk factors for recurrence following completion of antituberculosis therapy, we pooled data from three prospective observational Indian PTB co…
Abdelwahab MT, Court R, Everitt D, Diacon AH, Dawson R, et al.
… a WHO group B drug for the treatment of rifampin-resistant tuberculosis. QT prolongation, which is associated with fatal cardiac arrhythmias, is caused by several antitubercular drugs, including clofazimine, but there are no data quantifying the effect of clofazimine concentrati…
Zhang J, Lair C, Roubert C, Amaning K, Barrio MB, et al.
The emergence of drug-resistant tuberculosis has created an urgent need for new anti-tubercular agents. Here, we report the discovery of a series of macrolides called sequanamycins with outstanding in vitro and in vivo activity against Mycobacterium tuberculosis (Mtb). Sequanamyc…
Dutta NK, Tornheim JA, Fukutani KF, Paradkar M, Tiburcio RT, et al.
Pediatric tuberculosis (TB) remains a major global health problem. Improved pediatric diagnostics using readily available biosources are urgently needed. We used liquid chromatography-mass spectrometry to analyze plasma metabolite profiles of Indian children with active TB (n = 1…
Zhang W, Lun S, Liu LL, Xiao S, Duan G, et al.
…ntification of novel coumestan derivatives as Mycobacterium tuberculosis ( Mtb) Pks13-thioesterase (TE) domain inhibitors, with mutations observed (D1644G and N1640K) in the generated coumestan-resistant Mtb colonies. Herein, we report a further structure-activity relationships e…
Xu CH, Jeyashree K, Shewade HD, Xia YY, Wang LX, et al.
…onally representative studies globally in the post-2015 END tuberculosis (TB) era regarding wealth related inequity in the distribution of catastrophic costs due to TB care. Under the Chinese national tuberculosis programme setting, we aimed to assess extent of equity in distribu…
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, et al.
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), is…
Izudi J, Okello G, Bajunirwe F
…, the treatment regimen for previously treated persons with tuberculosis (TB) changed to a shorter regimen that lasts six months and consists of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. Few studies have examined treatment success rate (TSR) among previously treated pe…
Sukanya Wattanapokayakit, Waritta Sawaengdee, Punna Kunhapan, Pathida Prakongsup, Ayu Kasamatsu, et al.
… association between NAT2 acetylator status and the rate of tuberculosis (TB) retreatment among patients who had previously completed treatment for drug-susceptible TB. **METHODS:** We analyzed patients aged ≥18 years with TB who completed standard treatment containing IN…
Kuzyk PV, Savchyna МА, Gychka SG
…lymphoid hyperplasia in the patient with previous pulmonary tuberculosis. Materials and methods In the case of pulmonary nodular lymphoid hyperplasia clinical, laboratory, instrumental and morphological examination was performed. Results 44-year-old woman in 7 years after success…
Rigouts L, Miotto P, Schats M, Lempens P, Cabibbe AM, et al.
…tible and -resistant organisms - is common in Mycobacterium tuberculosis. In this study, we aimed to determine the limit of detection (LOD) of genotypic assays to detect gatifloxacin-resistant mutants in experimentally mixed populations. A fluoroquinolone-susceptible M. tuberculo…
Kwak N, Kim JY, Kim HJ, Kwon BS, Lee JH, et al.
… rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity by Xpert MTB/RIF assay or Mycobacterium tuberculosis culture withou…
Muzanyi G, Mafigiri DK, Salata R, Joloba M, Mukonzo J, et al.
…kground The current six months regimen for drug-susceptible tuberculosis (TB) is long, complex, and requires adherence monitoring. TB hair drug level assay is one innovative approach to monitor TB treatment adherence however, its acceptability in the context of African multi-cult…
Castro RAD, Ross A, Kamwela L, Reinhard M, Loiseau C, et al.
…in experimental treatment regimens against drug-susceptible tuberculosis. However, little is known on whether the genetic variation present in natural populations of Mycobacterium tuberculosis (Mtb) affects the evolution of FQ-resistance (FQ-R). To investigate this question, we u…
Eunsol Yang, Pieter Van Brantegem, Charles A Peloquin, Meredith B Brooks, Julia M Coit, et al.
…equent in the standard-of-care regimen for drug-susceptible tuberculosis, yet the association of each companion drug with hepatotoxicity has not been fully characterized. We examined the association between hepatotoxicity and the pharmacokinetics of rifampin and its companion dru…
Xiaoyun Du, Keqing Shi, Hao Zhang, Yingzhi Chong
Tuberculosis (TB) remains a leading global health threat, with the rise of drug-resistant (DR-TB) strains posing a significant impediment to disease control. An increasingly recognized and complex challenge is heteroresistance, the coexistence of drug-susceptible and drug-resista…
Jamal Hassan Mohamoud
Tuberculosis (TB) remains a major public health concern in Somalia, driven by prolonged conflict, population displacement, fragile health systems, and adverse social determinants of health. Although Somalia has made progress in expanding TB services and achieving favourable treat…
Yang Li, Lingyun Song, Zhen Feng, Xiaoqiang Zhang, Yan Miao, et al.
… ranging from 10 to 20 mg/kg for pulmonary drug-susceptible tuberculosis population. **METHODS:** The stage 1 of this seamless phase 2/3 randomized controlled trial recruited enrolled adults with drug-susceptible tuberculosis at 16 sites in China between 1 February 2023 and 29 S…